泰瓦如何做大做强成为百年老店雄踞世界仿制药龙头老大和处方药冠军，
有关泰瓦的发展历史，很值得我们研究学习，这个小国，缺乏资源，但能挤进全球药业20强，而且年复合成长超过许多大药厂，这里一定有许多经验和奥秘。建议园内大家收集有关泰瓦成长历史和经验的故事，报道和特写，让大家感受和学习别人办公司的经验和成功之路。
中国要做制药强国，不是喊口号，扔钱，买设备就能做到的，还有许多路要走，他山之石，可以攻玉，希望大家能分享和查询到有关信息，开展一些必要的讨论，
以下是从WIKI查到的一些信息，从该公司网站和历年年报及PPT中还可以找到许多有趣的故事和资料，
Public (NASDAQ: TEVA)
Founded 1901 1901 年创办成立的公司，2008年销售突破110亿美元。净收入23.7亿美元。全球员工28000人
Headquarters Petah Tikva, Israel
Key people Shlomo Yanai, President and Chief Executive Officer
Eli Hurvitz, Chairman
Eyal Desheh, Chief Financial Officer
Industry Pharmaceutical
Products Pharmaceuticals
Revenue $11.080 billion USD (FY 2008)
Net income $2.374 billion USD (FY 2008)
Employees 28,000 (2007) homepage
http://www.tevapharm.com/
Teva's earliest predecessor was Salomon, Levin, and Elstein Ltd., a wholesale distributor based in Jerusalem that was founded in 1901. During the 1930s, new immigrants from Europe founded several pharmaceutical companies including Teva, Assia, and Zori. In 1951, Teva raised capital through the newly founded Tel-Aviv Stock Exchange.
In 1964, Assia and Zori merged and acquired a controlling interest in Teva. In 1976, these three companies merged into the modern Teva Pharmaceutical Industries Ltd. In 1980, Teva continued to follow its vision of becoming one of the world's biggest Pharmaceutical companies by acquiring Ikapharm, then Israel's second largest drug manufacturer. [2]
In 1982, Teva was granted FDA approval for its Kfar Saba manufacturing plant, an essential milestone for marketing pharmaceuticals in the USA.
Teva's Innovative Research and Development has been granted approval for two innovative drugs: Copaxone (for the treatment of multiple sclerosis) in the mid-1990s, and Azilect (sold as Agilect in some countries) for treatment of Parkinson's disease in the 2000s. Several innovative compounds are in the pipeline, but the innovative arm carries far less weight in Teva (when compared to generics) than in any other top 20 pharmaceutical company.[citation needed]
On June 23, 2006, Teva (through a former Ivax subsidiary) received from the U.S. Food & Drug Administration a 180-day exclusivity period to sell simvastatin (Zocor) in the U.S. as a generic drug in all strengths except 80 mg. Teva presently competes with the maker of brand-name Zocor, Merck & Co.; Ranbaxy Laboratories, which has 180-day exclusivity for the 80 mg strength; and Dr. Reddy's Laboratories, whose authorized generic version (licensed by Merck) is exempt from exclusivity.
In 2005, Teva opened a new, state-of-the-art pharmaceutical manufacturing plant in Har Hotzvim, a technology park in Jerusalem. The plant received FDA approval in early 2007.
On December 24, 2007, Teva released an AB-rated generic alternative to Protonix.[3]
On December 23, 2008, Teva acquired Barr Pharmaceuticals for 7.5 billion USD, making Barr and Pliva (which Barr bought earlier) part of Teva.[4]
泰瓦2009年第一季度业绩良好
Teva reports First Quarter 2009 Results
Strong Non-GAAP Earnings; Significant Progress with Barr Integration
Jerusalem, Israel, May 5, 2009 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today reported results for the quarter ended March 31, 2009.
First Quarter Highlights:
* Net sales of $3.15 billion, up 22% compared to the first quarter of 2008. The appreciation of the U.S. Dollar adversely affected sales by $200 million with no impact on operating income.
* Non-GAAP net income of $634 million, up 4% compared with the first quarter of 2008. GAAP net income totaled $451 million.
* Non-GAAP EPS of $0.71, down 4% compared with the first quarter of 2008, due to higher financial expenses, tax rate and share count resulting from the Barr acquisition. GAAP diluted EPS totaled $0.51.
* Non-GAAP operating income of $826 million, up 14% compared to the first quarter of 2008. GAAP operating income totaled $538 million.
* Record global in-market sales of Copaxone? of $621 million, up 15% compared to the first quarter of 2008. Copaxone? continues to be the leading MS therapy in the U.S. and globally.
* Cash flow from operations of $733 million.
* Barr results included for the first time. Significant progress in the Barr integration.
Click Here for Financial Tables
"The year is off to a very strong start for Teva in terms of both financial results and strategic accomplishments, as we delivered growth throughout our various businesses and geographies. It was an outstanding quarter for our innovative and branded businesses, with record-breaking sales of Copaxone?--the global leader among treatments for MS--and excellent sales of our respiratory products and products from Barr's Women's Health franchise," commented Shlomo Yanai, Teva's President and Chief Executive Officer. "The Barr integration is proceeding ahead of schedule, and we now believe that we will derive even more value from this acquisition than we originally expected." 6 1 2 3 4 5 6 下一页 尾页
有关泰瓦的发展历史，很值得我们研究学习，这个小国，缺乏资源，但能挤进全球药业20强，而且年复合成长超过许多大药厂，这里一定有许多经验和奥秘。建议园内大家收集有关泰瓦成长历史和经验的故事，报道和特写，让大家感受和学习别人办公司的经验和成功之路。
中国要做制药强国，不是喊口号，扔钱，买设备就能做到的，还有许多路要走，他山之石，可以攻玉，希望大家能分享和查询到有关信息，开展一些必要的讨论，
以下是从WIKI查到的一些信息，从该公司网站和历年年报及PPT中还可以找到许多有趣的故事和资料，
Public (NASDAQ: TEVA)
Founded 1901 1901 年创办成立的公司，2008年销售突破110亿美元。净收入23.7亿美元。全球员工28000人
Headquarters Petah Tikva, Israel
Key people Shlomo Yanai, President and Chief Executive Officer
Eli Hurvitz, Chairman
Eyal Desheh, Chief Financial Officer
Industry Pharmaceutical
Products Pharmaceuticals
Revenue $11.080 billion USD (FY 2008)
Net income $2.374 billion USD (FY 2008)
Employees 28,000 (2007) homepage
http://www.tevapharm.com/
Teva's earliest predecessor was Salomon, Levin, and Elstein Ltd., a wholesale distributor based in Jerusalem that was founded in 1901. During the 1930s, new immigrants from Europe founded several pharmaceutical companies including Teva, Assia, and Zori. In 1951, Teva raised capital through the newly founded Tel-Aviv Stock Exchange.
In 1964, Assia and Zori merged and acquired a controlling interest in Teva. In 1976, these three companies merged into the modern Teva Pharmaceutical Industries Ltd. In 1980, Teva continued to follow its vision of becoming one of the world's biggest Pharmaceutical companies by acquiring Ikapharm, then Israel's second largest drug manufacturer. [2]
In 1982, Teva was granted FDA approval for its Kfar Saba manufacturing plant, an essential milestone for marketing pharmaceuticals in the USA.
Teva's Innovative Research and Development has been granted approval for two innovative drugs: Copaxone (for the treatment of multiple sclerosis) in the mid-1990s, and Azilect (sold as Agilect in some countries) for treatment of Parkinson's disease in the 2000s. Several innovative compounds are in the pipeline, but the innovative arm carries far less weight in Teva (when compared to generics) than in any other top 20 pharmaceutical company.[citation needed]
On June 23, 2006, Teva (through a former Ivax subsidiary) received from the U.S. Food & Drug Administration a 180-day exclusivity period to sell simvastatin (Zocor) in the U.S. as a generic drug in all strengths except 80 mg. Teva presently competes with the maker of brand-name Zocor, Merck & Co.; Ranbaxy Laboratories, which has 180-day exclusivity for the 80 mg strength; and Dr. Reddy's Laboratories, whose authorized generic version (licensed by Merck) is exempt from exclusivity.
In 2005, Teva opened a new, state-of-the-art pharmaceutical manufacturing plant in Har Hotzvim, a technology park in Jerusalem. The plant received FDA approval in early 2007.
On December 24, 2007, Teva released an AB-rated generic alternative to Protonix.[3]
On December 23, 2008, Teva acquired Barr Pharmaceuticals for 7.5 billion USD, making Barr and Pliva (which Barr bought earlier) part of Teva.[4]
泰瓦2009年第一季度业绩良好
Teva reports First Quarter 2009 Results
Strong Non-GAAP Earnings; Significant Progress with Barr Integration
Jerusalem, Israel, May 5, 2009 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today reported results for the quarter ended March 31, 2009.
First Quarter Highlights:
* Net sales of $3.15 billion, up 22% compared to the first quarter of 2008. The appreciation of the U.S. Dollar adversely affected sales by $200 million with no impact on operating income.
* Non-GAAP net income of $634 million, up 4% compared with the first quarter of 2008. GAAP net income totaled $451 million.
* Non-GAAP EPS of $0.71, down 4% compared with the first quarter of 2008, due to higher financial expenses, tax rate and share count resulting from the Barr acquisition. GAAP diluted EPS totaled $0.51.
* Non-GAAP operating income of $826 million, up 14% compared to the first quarter of 2008. GAAP operating income totaled $538 million.
* Record global in-market sales of Copaxone? of $621 million, up 15% compared to the first quarter of 2008. Copaxone? continues to be the leading MS therapy in the U.S. and globally.
* Cash flow from operations of $733 million.
* Barr results included for the first time. Significant progress in the Barr integration.
Click Here for Financial Tables
"The year is off to a very strong start for Teva in terms of both financial results and strategic accomplishments, as we delivered growth throughout our various businesses and geographies. It was an outstanding quarter for our innovative and branded businesses, with record-breaking sales of Copaxone?--the global leader among treatments for MS--and excellent sales of our respiratory products and products from Barr's Women's Health franchise," commented Shlomo Yanai, Teva's President and Chief Executive Officer. "The Barr integration is proceeding ahead of schedule, and we now believe that we will derive even more value from this acquisition than we originally expected." 6 1 2 3 4 5 6 下一页 尾页